Following the expiration of the Indian patent for semaglutide, over 40 Indian pharmaceutical companies are launching affordable generic versions of weight-loss drugs Ozempic and Wegovy, cutting prices by about 70%. Major firms like Sun Pharmaceutical, Dr. Reddy's, and Zydus Lifesciences have introduced various injectable and oral options with weekly or monthly costs significantly lower than original brands. These companies aim to capture a share of the global obesity market, projected to reach $100 billion by 2030, with plans to expand sales internationally. Meanwhile, Novo Nordisk continues to innovate with FDA approval of a higher-dose Wegovy and partnerships to offer GLP-1 weight-loss pills and injections in the U.S.
The European Commission has approved Novo Nordisk's Wegovy pill, the first oral GLP-1 receptor agonist for weight management across the EU. This approval covers adults with obesity or overweight with related health issues and follows positive clinica...
The global blood glucose monitoring system market, valued at $16.8 billion in 2025, is projected to grow to $39.4 billion by 2035 at an 8.9% CAGR. Growth is fueled by rising diabetes prevalence, advancements in AI-enabled monitoring devices, and incr...
